Göbel U, Körholz D, Janssen G, Schwamborn D, Jürgens H
Abt. für Hämatologie und Onkologie, Universität Düsseldorf.
Onkologie. 1987 Jun;10(3 Suppl):4-7.
Patients with cancer often have disturbances of cellular immunity. Changes of cellular immunity are frequently associated with tumor progression or an increased risk of a relapse. Cellular immunity is studied with an in vivo test system using 7 different recall antigens. We studied the cutaneous reaction of 80 children with various malignant diseases at time of diagnosis, at the end of the chemotherapy or prior to a relapse of the disease using the multitest Merieux. Before starting treatment patients with systemic diseases showed only a little response to the recall antigens. Patients with solid tumors had normal responses. No prognostic meaning of the multitest results were seen, if it was done before starting the treatment. At time of a relapse, these patients mostly had negative skin reactions using the multitest. It has to be studied if these results show a new systemic disease or if they are expression of an ongoing disturbance of cellular immunity of these patients.
癌症患者常常存在细胞免疫紊乱。细胞免疫的变化通常与肿瘤进展或复发风险增加相关。使用7种不同的回忆抗原,通过体内测试系统研究细胞免疫。我们使用梅里埃多联测试法,研究了80名患有各种恶性疾病的儿童在诊断时、化疗结束时或疾病复发前的皮肤反应。在开始治疗前,患有全身性疾病的患者对回忆抗原的反应很小。实体瘤患者的反应正常。如果在开始治疗前进行多联测试,其结果没有预后意义。在复发时,这些患者使用多联测试大多有阴性皮肤反应。这些结果是否表明出现了新的全身性疾病,或者是否是这些患者持续存在的细胞免疫紊乱的表现,还有待研究。